Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study
| Autor: | Daisuke Kato, Hiromi Tabuchi, Satoshi Uno |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
safety medicine.medical_specialty Urinary urgency Urology efficacy 030232 urology & nephrology Postmarketing surveillance Original Articles ‐ Clinical Urinary incontinence Persistence (computer science) Interval data 03 medical and health sciences 0302 clinical medicine Japan Internal medicine medicine Product Surveillance Postmarketing Humans Aged 030219 obstetrics & reproductive medicine business.industry Urinary Bladder Overactive Incidence (epidemiology) persistence Middle Aged medicine.disease mirabegron Thiazoles Urodynamics Treatment Outcome Neurology Overactive bladder Urological Agents Acetanilides Female Original Article overactive bladder medicine.symptom business Mirabegron medicine.drug |
| Zdroj: | Lower Urinary Tract Symptoms |
| ISSN: | 1757-5672 |
| Popis: | OBJECTIVE The aim of this study was to report the final 3-year results from a surveillance study evaluating the safety, efficacy, and persistence of mirabegron for treating overactive bladder (OAB) symptoms. METHODS Patients who had started mirabegron for the treatment of urinary urgency, daytime frequency, and urgency urinary incontinence symptoms associated with OAB were followed for 3 years. Adverse drug reactions (ADRs), residual urine volume measurements, OAB symptoms, Overactive Bladder Symptom Scores (OABSS), and treatment discontinuations were evaluated prospectively. Persistence was estimated using the Kaplan-Meier method. RESULTS Of the 1138 patients included in the study (mean ±SD age: 71.9 ± 11.0 years; 574 [50.4%] women), 97 (8.52%) experienced 109 ADRs, with the incidence of ADRs decreasing over time ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text